Elios Vision Announces Registration of Elios in France

Elios Vision announced that its Elios technology, which is used to treat glaucoma at the same time as cataract surgery, is now registered in France.

Elios does not require an implant and is designed to provide long-lasting results that may free patients from drop therapy.[1] The Elios technology uses excimer laser energy to create microscopic openings in the trabecular meshwork (TM) to re-establish the natural flow of aqueous.

“The Elios procedure is filling the gap for patients who don’t need an aggressive surgical approach, but are not doing well with drop therapy or would be much better off reducing their drop regimen,” glaucoma specialist Ike Ahmed, MD, said in a company news release. “Elios has been particularly impactful for cataract surgery in my practice. It just makes sense to combine Elios with cataract surgery when you’re already going into the eye.”

“Multiple clinical studies across Europe have demonstrated that Elios has a strong efficacy and safety profile, with significant advantages over other forms of microinvasive glaucoma surgery (MIGS),” said Elliot Friedman, Chief Executive Officer of Elios Vision.

In addition to being implant free, Elios’ use of an excimer laser avoids thermal or mechanical trauma.[1] The ten microchannels this technology creates have proven to be effective and long-lasting for up to 8 years,[2] according to Elios.

“The Elios technology appears to be a promising technology for lowering IOP and medication use in patients with glaucoma and has been used in other EU countries for several years. The fact that Elios uses a laser to enhance outflow is appealing as this makes the procedure less traumatic than conventional methods and avoids the use of implants,” says Prof Philippe Denis, Glaucoma Specialist, Hôpital de la Croix-Rousse, Lyon, France.

ELIOS was founded in partnership with MLase

Visit eliosvision.com for more information.

1. Töteberg-Harms et al. BMC Ophthalmology 2013

2. Riesen M, Funk J, Töteberg-Harms M. “Long-term treatment success and safety of combined phacoemulsification plus excimer laser trabeculostomy: an 8-year follow-up study”. Graefes Arch Clin Exp Ophthalmol. 2022 Jan 16.